In the 3xTg-AD mouse model, which develops both Aβ and tau pathologies, chronic treatment with LPS results in CDK5-dependent tau phosphorylation without affecting Aβ levels in adult animals (~ 6 months of age). Here, MAPT is linked to Alzheimer disease.